Qiagen (QGEN) Set to Announce Quarterly Earnings on Monday

Qiagen (NYSE:QGEN) is scheduled to be releasing its earnings data after the market closes on Monday, April 29th. Analysts expect Qiagen to post earnings of $0.44 per share for the quarter. Qiagen has set its FY 2024 guidance at 2.100- EPS.Investors that are interested in registering for the company’s conference call can do so using this link.

Qiagen (NYSE:QGEN) last released its quarterly earnings results on Tuesday, February 6th. The company reported $0.55 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.55. Qiagen had a return on equity of 12.99% and a net margin of 17.37%. The business had revenue of $509.00 million during the quarter, compared to analyst estimates of $500.77 million. During the same quarter in the previous year, the company posted $0.53 earnings per share. On average, analysts expect Qiagen to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Qiagen Stock Performance

NYSE:QGEN opened at $40.00 on Monday. The stock has a 50-day simple moving average of $42.74 and a two-hundred day simple moving average of $42.68. Qiagen has a 52-week low of $34.74 and a 52-week high of $47.70. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.62 and a current ratio of 1.99. The firm has a market capitalization of $9.13 billion, a PE ratio of 26.44, a P/E/G ratio of 3.37 and a beta of 0.41.

Institutional Investors Weigh In On Qiagen

Hedge funds have recently made changes to their positions in the company. Osaic Holdings Inc. increased its stake in Qiagen by 22.2% during the second quarter. Osaic Holdings Inc. now owns 5,728 shares of the company’s stock worth $244,000 after acquiring an additional 1,041 shares during the last quarter. Boothbay Fund Management LLC bought a new stake in Qiagen during the first quarter worth approximately $243,000. Nebula Research & Development LLC bought a new stake in Qiagen during the fourth quarter worth approximately $236,000. Delphia USA Inc. bought a new stake in Qiagen during the first quarter worth approximately $230,000. Finally, Vident Investment Advisory LLC bought a new stake in Qiagen during the fourth quarter worth approximately $228,000. 70.00% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have issued reports on QGEN shares. Morgan Stanley raised Qiagen from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $49.48 to $51.00 in a report on Friday, February 16th. Citigroup cut their price target on Qiagen from $61.86 to $60.00 and set a “buy” rating for the company in a report on Thursday, February 8th. Finally, JPMorgan Chase & Co. boosted their price target on Qiagen from $50.00 to $52.00 and gave the company an “overweight” rating in a report on Thursday, February 8th. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $51.69.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.